Cefodizime | CAS#69739-16-8 | cephalosporin antibiotic

MedKoo Cat#: 461653 | Name: Cefodizime

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefodizime is a 3rd generation cephalosporin antibiotic with broad spectrum activity against aerobic gram positive and gram negative bacteria.

Chemical Structure

Cefodizime

CAS#69739-16-8

Theoretical Analysis

MedKoo Cat#: 461653

Name: Cefodizime

CAS#: 69739-16-8

Chemical Formula: C20H20N6O7S4

Exact Mass: 584.0276

Molecular Weight: 584.65

Elemental Analysis: C, 41.09; H, 3.45; N, 14.37; O, 19.16; S, 21.93

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Cefodizime; HR 221; HR-221; HR221; S 771221; S-771221; S771221;

IUPAC/Chemical Name

(6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-(((5-(carboxymethyl)-4-methylthiazol-2-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

InChi Key

XDZKBRJLTGRPSS-BGZQYGJUSA-N

InChi Code

InChI=1S/C20H20N6O7S4/c1-7-10(3-11(27)28)37-20(22-7)36-5-8-4-34-17-13(16(30)26(17)14(8)18(31)32)24-15(29)12(25-33-2)9-6-35-19(21)23-9/h6,13,17H,3-5H2,1-2H3,(H2,21,23)(H,24,29)(H,27,28)(H,31,32)/b25-12-/t13-,17-/m1/s1

SMILES Code

O=C(C(N12)=C(CSC3=NC(C)=C(CC(O)=O)S3)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 584.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Wang B, Bian R, Wei C, Sun S, Gao P. [Cefodizime increases peripheral blood CD4/CD8 and Th1/Th2 ratios in senile patients with bacterial pneumonia]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2015 Apr;31(4):528-31. Chinese. PubMed PMID: 25854575. 2: Hu T, Liu Y. Probing the interaction of cefodizime with human serum albumin using multi-spectroscopic and molecular docking techniques. J Pharm Biomed Anal. 2015 Mar 25;107:325-32. doi: 10.1016/j.jpba.2015.01.010. Epub 2015 Jan 13. PubMed PMID: 25637820. 3: Wang P, Kan QC, Yu ZJ, Li L, Pan X. Effects of cefodizime on chemokines of liver tissues in mice with immunological hepatic injury. Chin Med J (Engl). 2011 Mar;124(5):746-50. PubMed PMID: 21518570. 4: Merighi M, Carlotto A, Guella L, Bonora S, Fibbia GC, Mazzi R, Lazzarini L, Mirandola F, Cruciani M, Concia E. Stability of cefodizime in solution and compatibility with other injectable drugs. J Chemother. 1994 Aug;6(4):243-5. PubMed PMID: 7830101. 5: Barradell LB, Brogden RN. Cefodizime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1992 Nov;44(5):800-34. Review. Erratum in: Drugs 1993 Jan;45(1):130. PubMed PMID: 1280568. 6: Limbert M, Bartlett RR, Dickneite G, Klesel N, Schorlemmer HU, Seibert G, Winkler I, Schrinner E. Cefodizime, an aminothiazolyl cephalosporin. IV. Influence on the immune system. J Antibiot (Tokyo). 1984 Dec;37(12):1719-26. PubMed PMID: 6098573. 7: Loffreda A, Lampa E, Lucarelli C, Amorena M, Contaldi C, Calderaro V, Rossi F. Pharmacokinetics of cefodizime in patients with various degrees of renal failure. Chemotherapy. 1999 Jan-Feb;45(1):1-7. PubMed PMID: 9876203. 8: Dagrosa EE, Hajdú P, Malerczyk V, de Looze S, Seeger K, Grötsch H. Dose linearity and other pharmacokinetics of cefodizime after single-dose intravenous administration. Clin Ther. 1987;10(1):18-31. Erratum in: Clin Ther 1988;10(4):466. PubMed PMID: 3450392. 9: Pruksachatvuthi S, Aswapokee N, Aswapokee P. In vitro antimicrobial activity of cefodizime, a third generation cephalosporin. J Med Assoc Thai. 1992 May;75(5):287-92. PubMed PMID: 1460409. 10: Wenisch C, Bartunek A, Zedtwitz-Liebenstein K, Hiesmayr M, Parschalk B, Pernerstorfer T, Graninger W. Prospective randomized comparison of cefodizime versus cefuroxime for perioperative prophylaxis in patients undergoing coronary artery bypass grafting. Antimicrob Agents Chemother. 1997 Jul;41(7):1584-8. PubMed PMID: 9210690; PubMed Central PMCID: PMC163964. 11: Mrestani Y, Bretschneider B, Härtl A, Brandsch M, Neubert RH. Influence of enhancers on the absorption and on the pharmacokinetics of cefodizime using in-vitro and in-vivo models. J Pharm Pharmacol. 2004 Apr;56(4):485-93. PubMed PMID: 15099444. 12: Matsushita H, Suzuki H, Sugiyama Y, Sawada Y, Iga T, Kawaguchi Y, Hanano M. Facilitated transport of cefodizime into the rat central nervous system. J Pharmacol Exp Ther. 1991 Nov;259(2):620-5. PubMed PMID: 1941610. 13: Korting HC, Schäfer-Korting M, Maass L, Klesel N, Mutschler E. Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers. Antimicrob Agents Chemother. 1987 Nov;31(11):1822-5. PubMed PMID: 3435129; PubMed Central PMCID: PMC175046. 14: Meyer B, Traunmueller F, Bojic A, Locker G, Schmid R, Winkler S, Thalhammer F. Single-dose pharmacokinetics of cefodizime in critically ill elderly patients. Int J Antimicrob Agents. 2006 Apr;27(4):335-8. Epub 2006 Mar 24. PubMed PMID: 16563704. 15: Asbach HW. A randomized, dose comparison study of cefodizime in the treatment of lower urinary tract infections in women. Infection. 1991 Mar-Apr;19(2):85-7. PubMed PMID: 2050425. 16: Braga PC, Sasso MD, Sala MT. Sub-MIC concentrations of cefodizime interfere with various factors affecting bacterial virulence. J Antimicrob Chemother. 2000 Jan;45(1):15-25. PubMed PMID: 10629008. 17: Lenfant B, Namour F, Logeais C, Coussediere D, Rivault O, Bryskier A, Surjus A. Pharmacokinetics of cefodizime following single doses of 0.5, 1.0, 2.0, and 3.0 grams administered intravenously to healthy volunteers. Antimicrob Agents Chemother. 1995 Sep;39(9):2037-41. PubMed PMID: 8540712; PubMed Central PMCID: PMC162877. 18: Nohjoh T, Suzuki H, Sawada Y, Sugiyama Y, Iga T, Hanano M. Transport of cefodizime, a novel third generation cephalosporin antibiotic, in isolated rat choroid plexus. J Pharmacol Exp Ther. 1989 Jul;250(1):324-8. PubMed PMID: 2746505. 19: Labro MT, el Benna J. Comparison of cefodizime with various cephalosporins for their indirect effect on the human neutrophil oxidative burst in vitro. J Antimicrob Chemother. 1990 Nov;26 Suppl C:49-57. PubMed PMID: 2127416. 20: Li G, Zhang Y, Ji M. [Clinical evaluation and immunomodulatory study of cefodizime]. Zhonghua Nei Ke Za Zhi. 1997 Nov;36(11):759-63. Chinese. PubMed PMID: 10451950.